Skin Graft for Skin Ulcer or Cellulitis DRG Reimbursement

DRG 575 encompasses inpatient stays for skin grafting related to skin ulcers or cellulitis when no Major Complication or Comorbidity or Complication or Comorbidity is present. This Diagnosis-Related Group defines the clinical scope for payment grouping and affects Medicare inpatient reimbursement by establishing the payment weight for these straightforward graft procedures.

DRG 575 Overview

DRG 575 covers inpatient admissions for patients receiving skin graft procedures for skin ulcers or cellulitis without a Major Complication or Comorbidity or a Complication or Comorbidity. It includes cases where the primary surgical intervention is grafting to promote wound closure in the setting of ulceration or soft tissue infection without additional documented higher-severity diagnoses. This Diagnosis-Related Group is used by Centers for Medicare & Medicaid Services for categorizing hospital stays and determining bundled Medicare inpatient reimbursement. Accurate clinical documentation and coding of the principal procedure and comorbid conditions influence assignment to this Diagnosis-Related Group and the corresponding payment.

Randomized controlled trials comparing alternative skin grafting techniques or biologic graft materials for lower extremity pressure ulcers and cellulitis-related soft tissue defects: these studies enroll hospitalized adults undergoing surgical debridement and immediate grafting to compare outcomes such as graft take rate, time to wound closure, intra‑hospital complication rates, and length of stay. They address an acute perioperative intervention and are directly relevant to surgeons, hospital care teams, and payers by informing choices that can reduce reoperation, shorten inpatient LOS, and lower complication‑related costs.
Comparative effectiveness studies of perioperative infection control and antibiotic stewardship strategies in patients with skin ulcers complicated by cellulitis: these observational or pragmatic trial designs evaluate different antibiotic duration strategies, timing of therapy relative to debridement/grafting, and adjunctive local antimicrobial dressings in adults with comorbidities (eg, diabetes, peripheral vascular disease). This research targets the high‑risk inpatient population typical of this DRG and is important for providers and payers because optimized protocols can reduce readmissions for surgical site infection and antimicrobial overuse, improving outcomes and resource utilization.
Post‑discharge outcomes and care‑transition studies assessing multidisciplinary follow‑up, home wound care delivery models, and readmission prevention for patients discharged after skin grafting for ulcers or cellulitis: these cohort or implementation trials track wound healing rates, outpatient visit frequency, emergency visits, and 30‑ to 90‑day readmission among older adults and medically complex patients. Such research focuses on the recovery and rehabilitation phase and is relevant to hospitals and payers interested in reducing avoidable readmissions, ensuring continuity of care, and evaluating cost‑effectiveness of post‑acute services like home nursing and telehealth wound monitoring.

Randomized controlled trials comparing alternative skin grafting techniques or biologic graft materials for lower extremity pressure ulcers and cellulitis-related soft tissue defects: these studies enroll hospitalized adults undergoing surgical debridement and immediate grafting to compare outcomes such as graft take rate, time to wound closure, intra‑hospital complication rates, and length of stay. They address an acute perioperative intervention and are directly relevant to surgeons, hospital care teams, and payers by informing choices that can reduce reoperation, shorten inpatient LOS, and lower complication‑related costs.
Comparative effectiveness studies of perioperative infection control and antibiotic stewardship strategies in patients with skin ulcers complicated by cellulitis: these observational or pragmatic trial designs evaluate different antibiotic duration strategies, timing of therapy relative to debridement/grafting, and adjunctive local antimicrobial dressings in adults with comorbidities (eg, diabetes, peripheral vascular disease). This research targets the high‑risk inpatient population typical of this DRG and is important for providers and payers because optimized protocols can reduce readmissions for surgical site infection and antimicrobial overuse, improving outcomes and resource utilization.
Post‑discharge outcomes and care‑transition studies assessing multidisciplinary follow‑up, home wound care delivery models, and readmission prevention for patients discharged after skin grafting for ulcers or cellulitis: these cohort or implementation trials track wound healing rates, outpatient visit frequency, emergency visits, and 30‑ to 90‑day readmission among older adults and medically complex patients. Such research focuses on the recovery and rehabilitation phase and is relevant to hospitals and payers interested in reducing avoidable readmissions, ensuring continuity of care, and evaluating cost‑effectiveness of post‑acute services like home nursing and telehealth wound monitoring.

OpenPayer

Summary & Overview

Skin Graft for Skin Ulcer or Cellulitis without CC/MCC: Inpatient Reimbursement Overview

DRG 575 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes